Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed unresectable stage IV melanoma~* Measurable metastatic disease~* No uncontrolled brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 70-100%~Life expectancy:~* More than 12 weeks~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* SGOT and SGPT no greater than 3 times ULN~* Alkaline phosphatase no greater than 3 times ULN~Renal:~* BUN no greater than 1.5 times ULN~* Creatinine no greater than 1.5 times ULN~Cardiovascular:~* No significant cardiovascular disease~Other:~* No non-malignant systemic disease~* No acute infection requiring IV antibiotics~* No alcohol or substance abuse~* No other condition, disease, or history of other illness that would preclude study participation~* No hypersensitivity, allergic reactions, or intolerance to study drugs~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy~* No prior interleukin-2~* No other concurrent immunotherapy~* No concurrent investigational vaccines or immunomodulatory agents~* No other concurrent growth factors~Chemotherapy:~* At least 4 weeks since prior chemotherapy~* No prior temozolomide~* No other concurrent anticancer chemotherapy~Endocrine therapy:~* No concurrent steroids (including corticosteroids)~Radiotherapy:~* At least 4 weeks since prior radiotherapy~Surgery:~* See Disease Characteristics~* At least 3 weeks since prior major surgery~Other:~* At least 30 days since prior immune-based therapy~* No concurrent participation in other clinical trials with investigational drugs~* No other concurrent anticancer drugs~* No concurrent immunosuppressive therapy~* No concurrent levamisole or cimetidine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).